Fig. 4

Persisting pre-leukemic mutations and minimal residual disease. MRD levels were assessed a by qPCR in 46 NPM1-mutated patients and b by flow cytometry in 82 patients. Boxplots show the median, 25th/75th percentile, and minimum/maximum level of a NPM1mut/ABL1 ratio and b LAIP-positive cells, for patients with and without persisting mutations in the remission sample